News

Tyvaso Becomes 1st PH-ILD Treatment Approved in US

Tyvaso (inhaled treprostinil) has become the first treatment approved in the U.S. for people with pulmonary hypertension associated with interstitial lung disease (PH-ILD). The U.S. Food and Drug Administration (FDA) approved Tyvaso, developed by United Therapeutics, to improve exercise ability in PH-ILD patients, the company said. “The…

Some PAH Patients May Benefit from Switch to Adempas

Intermediate-risk pulmonary arterial hypertension (PAH) patients may see their symptoms improve after switching from phosphodiesterase-5 inhibitors (PDE-5i) to Adempas (riociguat), results from the Phase 4 REPLACE clinical trial show. The transition to Adempas also appears to be a safer option than with PDE-5i maintenance therapy. The study, “Switching…

Study Pinpoints Altered Biological Pathways in Endothelial Cells

Several proteins involved in vascular remodeling, metabolism, and oxidative stress are not properly regulated in endothelial cells from patients with chronic thromboembolic pulmonary hypertension (CTEPH), a study found. The study, “Protein network analyses of pulmonary endothelial cells in chronic thromboembolic pulmonary hypertension,” was published in the journal…

PHA Publishes Guide on Risk Factors, Treatments in Newborn PH

The Pulmonary Hypertension Association (PHA) has published a guide to educate healthcare providers and parents on persistent pulmonary hypertension of the newborn (PPHN). The goal, the PHA said, is to help identify the disease right away, so as to start early treatment to prevent complications for the baby.

PulmoSIM Therapeutics Opens With Focus on Better Treating PAH

VeriSIM Life has opened PulmoSIM Therapeutics, its pharmaceutical subsidiary focused on developing treatments for pulmonary arterial hypertension (PAH) and idiopathic pulmonary fibrosis (IPF), before moving to other rare respiratory diseases. “We are thrilled to announce the launch of PulmoSIM as it demonstrates the indefinite capabilities of the VeriSIM’s…